| Autor: |
Fadaki N; Department of Surgery, The Center for Melanoma Research and Treatment in California Pacific Medical Center, San Francisco, California, USA., Cardona-Huerta S, Martineau L, Thummala S, Cheng ST, Bunker SR, Garcia-Kennedy R, Wang W, Minor D, Kashani-Sabet M, Leong SP |
| Jazyk: |
angličtina |
| Zdroj: |
BMJ case reports [BMJ Case Rep] 2012 Oct 22; Vol. 2012. Date of Electronic Publication: 2012 Oct 22. |
| DOI: |
10.1136/bcr-2012-007034 |
| Abstrakt: |
A patient with a bulky inoperable stage IIIC melanoma involving the left axilla and neck from a primary of the left medial elbow received vemurafenib as neo-adjuvant treatment. Based on the molecular analysis, BRAF V600E mutation was present. After 4 months of vemurafinib treatment, the tumours shrank to less than 50% of original clinical size and allowed the surgeons to perform a left modified radical neck dissection and left radical axillary dissection. Pathological analysis of specimen revealed viable metastatic cells only in 1 of 40 nodes resected in the neck and axillary dissection, accounting for over 98% pathological response. Other lymph nodes had a mixture of foamy histiocytic inflammatory reaction fibrosis and islands of necrotic tissues. After recovery from surgery, vemurafenib was resumed and continued for 6 months. He remained disease free 6 months after surgery. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
